Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Genome-wide association studies have begun to elucidate the genetic architecture of type 2 diabetes. We examined whether single nucleotide polymorphisms (SNPs) identified through targeted complementary approaches affect diabetes incidence in the at-risk population of the Diabetes Prevention Program (DPP) and whether they influence a response to preventive interventions. RESEARCH DESIGN AND METHODS: We selected SNPs identified by prior genome-wide association studies for type 2 diabetes and related traits, or capturing common variation in 40 candidate genes previously associated with type 2 diabetes, implicated in monogenic diabetes, encoding type 2 diabetes drug targets or drug-metabolizing/transporting enzymes, or involved in relevant physiological processes. We analyzed 1,590 SNPs for association with incident diabetes and their interaction with response to metformin or lifestyle interventions in 2,994 DPP participants. We controlled for multiple hypothesis testing by assessing false discovery rates. RESULTS: We replicated the association of variants in the metformin transporter gene SLC47A1 with metformin response and detected nominal interactions in the AMP kinase (AMPK) gene STK11, the AMPK subunit genes PRKAA1 and PRKAA2, and a missense SNP in SLC22A1, which encodes another metformin transporter. The most significant association with diabetes incidence occurred in the AMPK subunit gene PRKAG2 (hazard ratio 1.24, 95% CI 1.09–1.40, P = 7 × 10−4). Overall, there were nominal associations with diabetes incidence at 85 SNPs and nominal interactions with the metformin and lifestyle interventions at 91 and 69 mostly nonoverlapping SNPs, respectively. The lowest P values were consistent with experiment-wide 33% false discovery rates. CONCLUSIONS: We have identified potential genetic determinants of metformin response. These results merit confirmation in independent samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Inference of Population Structure Using Multilocus Genotype Data
Pritchard, J. K., Stephens, M., & Donnelly, P. (2000) · Genetics · doi:10.1093/genetics/155.2.945 · Cited by 33,908
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843
Self-citationThe Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · cited 9×
“Category n Candidate genes (n SNPs) 1,256 Comprehensive coverage 1,241 Monogenic diabetes 317 ABCC8 (84), GCK (37), HNF1A (20), HNF1B (74), HNF4A (66), KCNJ11 (9), NEUROD1 (14), PDX1 (13) Monogenic obesity 21 MC4R (21) Previously associated with type 2 diabetes 60 CAPN10 (33), PTPN1 (27) Drug targets 190 PPARG (59), P…”
BackgroundInfluentialWellcome Trust Case Control Consortium, Zeggini, E., Scott, L. J., Saxena, R., Voight, B. F., Marchini, J. L., Hu, T., de Bakker, P. I., Abecasis, G. R., Almgren, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.120 · Cited by 1,864
Self-citationthe GIANT Consortium (2009) · Nature Genetics · doi:10.1038/ng.287 · Cited by 1,720
Efficiency and power in genetic association studies
de Bakker, P. I. W., Yelensky, R., Pe'er, I., Gabriel, S. B., Daly, M. J., & Altshuler, D. (2005) · Nature Genetics · doi:10.1038/ng1669 · Cited by 1,688
Self-citation
Research works printed but not linked: 1
- Li, 2006, Mach 1.0: Rapid haplotype reconstruction and missing genotype inference, Am J Hum Genet S, 79, 2290
Cited by
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
“Another intronic variant of MATE1 (C>T, SNP rs8065082) is possibly associated with a lesser progression of prediabetes to diabetes([97]) but there has been no study on any influence on the pharmacokinetic parameters.”
BackgroundUnderstanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Schultze, S. M., Hemmings, B. A., Niessen, M., & Tschopp, O. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002109 · Cited by 540
Metformin pathways: pharmacokinetics and pharmacodynamics
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283559b22 · Cited by 495
Metformin Action: Concentrations Matter
He, L., & Wondisford, F. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.003 · Cited by 448
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Self-citationTherapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Hostalek, U., Gwilt, M., & Hildemann, S. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 278
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
MetGen Investigators, Zhou, K., DPP Investigators, ACCORD Investigators, Yee, S. W., Seiser, E. L., van Leeuwen, N., Tavendale, R., Bennett, A. J., Groves, C. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3632 · Cited by 234
Self-citationfor the Diabetes Prevention Program Research Group, Aroda, V. R., Knowler, W. C., Crandall, J. P., Perreault, L., Edelstein, S. L., Jeffries, S. L., Molitch, M. E., Pi-Sunyer, X., Darwin, C., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4361-9 · Cited by 194
Self-citationChung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05181-w · Cited by 203
Self-citationStocker, S. L., Morrissey, K. M., Yee, S. W., Castro, R. A., Xu, L., Dahlin, A., Ramirez, A. H., Roden, D. M., Wilke, R. A., McCarty, C. A., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.210 · Cited by 193
Knowler (2011) · doi:10.1001/archinternmed.2011.367 · Cited by 194
Knowler, W. C. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_16-1 · Cited by 194
Self-citationHivert, M.-F., Jablonski, K. A., Perreault, L., Saxena, R., McAteer, J. B., Franks, P. W., Hamman, R. F., Kahn, S. E., Haffner, S., the DIAGRAM Consortium, et al. (2011) · Diabetes · doi:10.2337/db10-1119 · Cited by 191
Self-citationType 2 Diabetes Genetics: Beyond GWAS
Sanghera, D. K., & Blackett, P. R. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000198 · Cited by 188
Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects
Emami Riedmaier, A., Fisel, P., Nies, A. T., Schaeffeler, E., & Schwab, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.11.005 · Cited by 161
Gene-Environment and Gene-Treatment Interactions in Type 2 Diabetes
Franks, P. W., Pearson, E., & Florez, J. C. (2013) · Diabetes Care · doi:10.2337/dc12-2211 · Cited by 154
Self-citationA Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to Metformin
Choi, J. H., Yee, S. W., Ramirez, A. H., Morrissey, K. M., Jang, G. H., Joski, P. J., Mefford, J. A., Hesselson, S. E., Schlessinger, A., Jenkins, G., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.165 · Cited by 156
Yee, S. W., Brackman, D. J., Ennis, E. A., Sugiyama, Y., Kamdem, L. K., Blanchard, R. L., Galetin, A., Zhang, L., & Giacomini, K. M. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1098 · Cited by 155
Tarāsova, L., Kalniņa, I., Geldnere, K., Bumbure, A., Ritenberga, R., Ņikitina-Zaķe, L., Frīdmanis, D., Vaivade, I., Pīrāgs, V., & Kloviņš, J. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283561666 · Cited by 149
Metformin Pharmacogenomics: Current Status and Future Directions
Pawlyk, A. C., Giacomini, K. M., McKeon, C., Shuldiner, A. R., & Florez, J. C. (2014) · Diabetes · doi:10.2337/db13-1367 · Cited by 136
Self-citationDifferential effects of metformin on age related comorbidities in older men with type 2 diabetes
Wang, C.-P., Lorenzo, C., Habib, S. L., Jo, B., & Espinoza, S. E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.01.013 · Cited by 134
Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis
Zhou, K., Donnelly, L., Yang, J., Li, M., Deshmukh, H., Van Zuydam, N., Ahlqvist, E., Spencer, C. C., Groop, L., Morris, A. D., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70050-6 · Cited by 124
Genetics of Type 2 Diabetes: Insights into the Pathogenesis and Its Clinical Application
Sun, X., Yu, W., & Hu, C. (2014) · BioMed Research International · doi:10.1155/2014/926713 · Cited by 111
The Pharmacogenetics of Type 2 Diabetes: A Systematic Review
Maruthur, N. M., Gribble, M. O., Bennett, W. L., Bolen, S., Wilson, L. M., Balakrishnan, P., Sahu, A., Bass, E., Kao, W. H. L., & Clark, J. M. (2014) · Diabetes Care · doi:10.2337/dc13-1276 · Cited by 119
Tkáč, I., Klimčáková, L., Javorský, M., Fabianová, M., Schroner, Z., Hermanová, H., Babjaková, E., & Tkáčová, R. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01691.x · Cited by 127
Delahanty, L. M., Pan, Q., Jablonski, K. A., Watson, K. E., McCaffery, J. M., Shuldiner, A., Kahn, S. E., Knowler, W. C., Florez, J. C., Franks, P. W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1328 · Cited by 116
Self-citationVariants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta‐Analysis
Dujic, T., Zhou, K., Yee, S., van Leeuwen, N., de Keyser, C., Javorský, M., Goswami, S., Zaharenko, L., Hougaard Christensen, M., Out, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.567 · Cited by 108
Personalized medicine in diabetes mellitus: current opportunities and future prospects
Kleinberger, J. W., & Pollin, T. I. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12757 · Cited by 124
Self-citationPharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine
Mannino, G. C., Andreozzi, F., & Sesti, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3109 · Cited by 117
Genetics of diabetes-associated microvascular complications
Lyssenko, V., & Vaag, A. A. (2023) · Diabetologia · doi:10.1007/s00125-023-05964-x · Cited by 113
Precision medicine in diabetes prevention, classification and management
Xie, F., Chan, J. C., & Ma, R. C. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12830 · Cited by 97
Gene‐lifestyle interaction on risk of type 2 diabetes: A systematic review
Dietrich, S., Jacobs, S., Zheng, J., Meidtner, K., Schwingshackl, L., & Schulze, M. B. (2019) · Obesity Reviews · doi:10.1111/obr.12921 · Cited by 107
The pharmacogenetics of metformin
Florez, J. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4335-y · Cited by 90
Self-citationMetformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome
Sam, S., & Ehrmann, D. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4306-3 · Cited by 93
Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters
Schlessinger, A., Khuri, N., Giacomini, K. M., & Šali, A. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313070007 · Cited by 95
Xiao, D., Yu, G., Li, X., Yin, J., Zheng, W., Qiu, X., Xiao, L., Liu, R., Wang, S., Gong, W., et al. (2016) · International Journal of Endocrinology · doi:10.1155/2016/4350712 · Cited by 102
A Review of Clinical Pharmacogenetics Studies in African Populations
Radouani, F., Zass, L. J., Hamdi, Y., da Rocha, J., Sallam, R. M., Abdelhak, S., Ahmed, S., Azzouzi, M., Benamri, I., Benkahla, A., et al. (2020) · Personalized Medicine · doi:10.2217/pme-2019-0110 · Cited by 82
García-Calzón, S., Perfilyev, A., Männistö, V., de Mello, V. D., Nilsson, E., Pihlajamäki, J., & Ling, C. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0400-0 · Cited by 79
Susceptibility to type 2 diabetes mellitus—from genes to prevention
Hivert, M.-F., Vassy, J. L., & Meigs, J. B. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.11 · Cited by 77
Florez, J. C., Jablonski, K. A., Taylor, A., Mather, K. J., Horton, E. S., White, N. H., Barrett-Connor, E. L., Knowler, W. C., Shuldiner, A. R., & Pollin, T. I. (2012) · Diabetes Care · doi:10.2337/dc11-2301 · Cited by 78
Self-citationFrom pharmacogenetics to pharmaco-omics: Milestones and future directions
Auwerx, C., Sadler, M. C., Reymond, A., & Kutalik, Z. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2022.100100 · Cited by 90
Pharmacogenetics of Type 2 Diabetes—Progress and Prospects
Nasykhova, Y. A., Tonyan, Z. N., Mikhailova, A. A., Danilova, M. M., & Glotov, A. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186842 · Cited by 80
Lifestyle precision medicine: the next generation in type 2 diabetes prevention?
Mutie, P. M., Giordano, G. N., & Franks, P. W. (2017) · BMC Medicine · doi:10.1186/s12916-017-0938-x · Cited by 73
Self-citationAn Update on the Pharmacogenomics of Metformin: Progress, Problems and Potential
Todd, J. N., & Florez, J. C. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.21 · Cited by 77
Self-citationPharmacogenomics in diabetes mellitus: insights into drug action and drug discovery
Zhou, K., Pedersen, H., Dawed, A. Y., & Pearson, E. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.51 · Cited by 78
Nies, A. T., Damme, K., Kruck, S., Schaeffeler, E., & Schwab, M. G. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1728-5 · Cited by 72
Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
Florez, J. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4227-1 · Cited by 72
Self-citationType 2 diabetes and obesity: genomics and the clinic
Travers, M. E., & McCarthy, M. I. (2011) · Human Genetics · doi:10.1007/s00439-011-1023-8 · Cited by 77
The metabolic sensor AMPK: Twelve enzymes in one
Smiles, W. J., Ovens, A. J., Oakhill, J. S., & Kofler, B. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102042 · Cited by 74
Metformin for diabetes prevention: update of the evidence base
Gottwald‐Hostalek, U., & Campbell, I. W. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1955667 · Cited by 80
Goswami, S., Yee, S. W., Stocker, S., Mosley, J. D., Kubo, M., Castro, R., Mefford, J. A., Wen, C., Liang, X., Witte, J., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.109 · Cited by 66
Pharmacogenetic studies update in type 2 diabetes mellitus
Singh, S. T., Usman, K., & Banerjee, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i15.302 · Cited by 77
Metformin from mother to unborn child-are there unwarranted effects?
Nguyen, L., Chan, S.-Y., & Teo, A. K. K. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.047 · Cited by 67
Targeting the Consequences of the Metabolic Syndrome in the Diabetes Prevention Program
Goldberg, R. B., & Mather, K. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241893 · Cited by 67
Pharmacogenomics of Oral Antidiabetic Medications: Current Data and Pharmacoepigenomic Perspective
Manolopoulos, V. G., Ragia, G., & Tavridou, A. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.65 · Cited by 74
Metformin: Past, Present, and Future
Chaudhary, S., & Kulkarni, A. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01539-1 · Cited by 68
Lam, Y. W. F. (2013) · ISRN Pharmacology · doi:10.1155/2013/641089 · Cited by 71
García-Calzón, S., Perfilyev, A., Martinell, M., Ustinova, M., Kalamajski, S., Franks, P. W., Bacos, K., Elbere, I., Pihlajamäki, J., Volkov, P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1803 · Cited by 65
Self-citationHibma, J. E., Zur, A. A., Castro, R. A., Wittwer, M., Keizer, R. J., Yee, S. W., Goswami, S., STOCKER, S. L., Zhang, X., Huang, Y. L., et al. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0346-3 · Cited by 64
Insights into the genetic basis of type 2 diabetes
Kato, N. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12067 · Cited by 65
Smoliga, J. M., Colombo, E. S., & Campen, M. J. (2013) · Aging · doi:10.18632/aging.100579 · Cited by 64
Segrè, A. V., Wei, N., MAGIC Investigators, Altshuler, D., & Florez, J. C. (2014) · Diabetes · doi:10.2337/db14-0703 · Cited by 58
Self-citationThe Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial
Pedersen, A. J. T., Stage, T. B., Glintborg, D., Andersen, M., & Christensen, M. M. H. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12874 · Cited by 54
Precision Medicine in Diabetes: Is It Time?
Florez, J. C. (2016) · Diabetes Care · doi:10.2337/dc16-0586 · Cited by 57
Self-citationYeung, S. L. A., & Schooling, C. M. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000872 · Cited by 56
The genetics of type 2 diabetes and its clinical relevance
Pal, A., & McCarthy, M. (2013) · Clinical Genetics · doi:10.1111/cge.12055 · Cited by 52
Jiang, G., Luk, A. O. Y., Tam, C. H. T., Lau, E. S. H., Ozaki, R., Chow, E., Kong, A. P. S., Lim, C. K. P., Lee, K. F., Siu, S. C., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003209 · Cited by 54
2020 vision – An overview of prospects for diabetes management and prevention in the next decade
Wang, C., Neil, D. L., & Home, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.007 · Cited by 57
Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays
Roth, A. D., & Lee, M. (2017) · BioMed Research International · doi:10.1155/2017/9176937 · Cited by 54
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition
Zazuli, Z., Duin, N. J. C. B., Jansen, K., Vijverberg, S. J. H., der Zee, A. H. M., & Masereeuw, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186627 · Cited by 52
Damanhouri, Z. A., Alkreathy, H. M., Alharbi, F. A., Abualhamail, H., & Ahmad, M. S. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.77206 · Cited by 58
Galán-Chilet, I., Grau-Pérez, M., de Marco, G., Güallar, E., Martín-Escudero, J. C., Dominguez-Lucas, A., González-Manzano, I., López‐Izquierdo, R., Briongos-Figuero, L. S., Redón, J., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.022 · Cited by 51
Pharmacogenetics of Oral Antidiabetic Drugs
Becker, M. L., Pearson, E. R., & Tkáč, I. (2013) · International Journal of Endocrinology · doi:10.1155/2013/686315 · Cited by 52
Blackett, P. R., & Sanghera, D. K. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.079 · Cited by 51
Vassy, J. L., OʼBrien, K., Waxler, J. L., Park, E. R., Delahanty, L. M., Florez, J. C., Meigs, J. B., & Grant, R. W. (2012) · Medical Decision Making · doi:10.1177/0272989x11431608 · Cited by 54
Self-citationMaruthur, N. M., Clark, J. M., Fu, M., Kao, W. H. L., & Shuldiner, A. R. (2014) · Diabetologia · doi:10.1007/s00125-014-3419-1 · Cited by 47
Self-citationPharmacogenetics and personalized treatment of type 2 diabetes
Semiz, S., Dujić, T., & Čaušević, A. (2013) · Biochemia Medica · doi:10.11613/bm.2013.020 · Cited by 54
NIH Precision Medicine Initiative: Implications for Diabetes Research
FRADKIN, J. E., Hanlon, M. C., & Rodgers, G. P. (2016) · Diabetes Care · doi:10.2337/dc16-0541 · Cited by 45
Personalized medicine in Type 2 Diabetes
Liao, W., & Tsai, F. (2014) · Biomedicine · doi:10.7603/s40681-014-0008-z · Cited by 47
Jha, R. M., Koleck, T. A., Puccio, A. M., Okonkwo, D. O., Park, S., Zusman, B. E., Clark, R. S. B., Shutter, L., Wallisch, J. S., Empey, P. E., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317741 · Cited by 41
Pan, Q., Delahanty, L. M., Jablonski, K. A., Knowler, W. C., Kahn, S. E., Florez, J. C., & Franks, P. W. (2013) · Obesity · doi:10.1002/oby.20459 · Cited by 42
Self-citationIndividualized Therapy for Type 2 Diabetes: Clinical Implications of Pharmacogenetic Data
Mannino, G. C., & Sesti, G. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0002-7 · Cited by 45
Reséndiz‐Abarca, C. A., Flores‐Alfaro, E., Suárez‐Sánchez, F., Cruz, M., Valladares‐Salgado, A., Alarcón‐Romero, L. D. C., Vázquez‐Moreno, M. A., Wacher, N. H., & Gómez-Zamudio, J. H. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1425 · Cited by 42
Hivert, M.-F., Christophi, C. A., Franks, P. W., Jablonski, K. A., Ehrmann, D. A., Kahn, S. E., Horton, E. S., Pollin, T. I., Mather, K. J., Perreault, L., et al. (2016) · Diabetes · doi:10.2337/db15-0950 · Cited by 38
Self-citationNagaraj, S. B., Sidorenkov, G. A., van Boven, J. F. M., & Denig, P. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13860 · Cited by 42
Pollin, T. I., Isakova, T., Jablonski, K. A., de Bakker, P. I. W., Taylor, A., McAteer, J. B., Pan, Q., Horton, E. S., Delahanty, L. M., Altshuler, D., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002895 · Cited by 38
Self-citationPharmacogenetics in type 2 diabetes: potential implications for clinical practice
Huang, C., & Florez, J. C. (2011) · Genome Medicine · doi:10.1186/gm292 · Cited by 44
Self-citationArimany-Nardí, C., Koepsell, H., & Pastor‐Anglada, M. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.78 · Cited by 35
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
Pearson, E. R., Dawed, A. Y., & Zhou, K. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s84854 · Cited by 49
Hall, M. A., Wallace, J. R., Lucas, A., Kim, D., Basile, A. O., Verma, S. S., McCarty, C. A., Brilliant, M. H., Peissig, P. L., Kitchner, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00802-2 · Cited by 35
MATE2 Expression Is Associated With Cancer Cell Response to Metformin
Chowdhury, S., Yung, E., Pintilie, M., Muaddi, H., Chaib, S., Yeung, M., Fusciello, M., Sykes, J., Pitcher, B., Hagenkort, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165214 · Cited by 33
Li, Z., Ye, C., Zhao, T., & Yang, L. (2020) · BMC Public Health · doi:10.1186/s12889-020-09130-5 · Cited by 35
Franks, P. W., Christophi, C. A., Jablonski, K. A., Billings, L. K., Delahanty, L. M., Horton, E. S., Knowler, W. C., & Florez, J. C. (2013) · Diabetologia · doi:10.1007/s00125-013-3133-4 · Cited by 37
Self-citationObesity-Related Genomic Loci Are Associated with Type 2 Diabetes in a Han Chinese Population
Kong, X., Zhang, X., Zhao, Q., He, J., Chen, L., Zhao, Z., Li, Q., Ge, J., Chen, G., Guo, X., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104486 · Cited by 33
Gene × Environment Interactions in Obesity: The State of the Evidence
Ahmad, S., Varga, T. V., & Franks, P. W. (2013) · Human Heredity · doi:10.1159/000351070 · Cited by 38
Self-citationHuman intelectin-1 (ITLN1) genetic variation and intestinal expression
Nonnecke, E. B., Castillo, P. A., Dugan, A. E., Almalki, F., Underwood, M. A., de la Motte, C. A., Yuan, W., Lu, W., Shen, B., Johansson, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92198-9 · Cited by 31
Bodhini, D., Morton, R. W., Santhakumar, V., Nakabuye, M., Pomares‐Millan, H., Clemmensen, C., Fitzpatrick, S. L., Guasch‐Ferré, M., Pankow, J. S., Ried‐Larsen, M., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00363-0 · Cited by 35
Self-citationKetterer, C., Heni, M., Stingl, K. T., Tschritter, O., Linder, K., Wagner, R. J., Machicao, F. E., Häring, H., Preissl, H. T., Staiger, H., et al. (2013) · Obesity · doi:10.1002/oby.20573 · Cited by 31
Metadata
- Authors
- Jablonski, K. A., McAteer, J. B., de Bakker, P. I. W., Franks, P. W., Pollin, T. I., Hanson, R. L., Saxena, R., Fowler, S., Shuldiner, A. R., Knowler, W. C., Altshuler, D., Florez, J. C., & for the Diabetes Prevention Program Research Group
- Affiliations
- George Washington University (US)
- Broad Institute (US)
- Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts;
- Lund University (SE)
- University of Maryland, Baltimore (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts;
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-08-03
- Volume
- 59
- Issue
- 10
- Pages
- 2672-2681
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3279522
- OpenAlex
- W2137393786
- Cited by
- 271
- References
- 35
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 10 · 2023: 17 · 2022: 12 · 2021: 13 · 2020: 16 · 2019: 18 · 2018: 19 · 2017: 21 · 2016: 24 · 2015: 18 · 2014: 25 · 2013: 25 · 2012: 23
- FWCI
- 11.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072041, U01DK048489)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, single nucleotide polymorphisms, metformin response, lifestyle intervention, Diabetes Prevention Program, SLC47A1, AMPK, PRKAG2, STK11, PRKAA1, PRKAA2, SLC22A1, genetic susceptibility, gene-environment interaction, diabetes prevention
- MeSH terms
- Adult, Diabetes Mellitus, Diabetes Mellitus, Type 2, Ethnicity, Female, Genotype, Hemeproteins, Humans, Life Style, Male, Metformin, Middle Aged, Genetic Variation, Body Mass Index, Incidence, Polymorphism, Single Nucleotide, Organic Cation Transport Proteins, Racial Groups, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.